More than 20,000 NHS patients across at least 200 GP surgeries in England are participating in a new trial using blood tests to detect signs of up to 13 different cancers at an early stage. The government-funded STRIDE-RCT study evaluates whether multi-marker blood tests can help primary care doctors accurately triage patients presenting with vague abdominal symptoms.
The STRIDE-RCT trial, developed by the University of Birmingham, aims to address the diagnostic challenges surrounding abdominal cancers, which are frequently detected late because their initial signs resemble less serious conditions. Patients aged 45 and over who visit participating GP practices with symptoms such as persistent bloating, abdominal discomfort, or pain are offered the opportunity to take part in the research.
How STRIDE-RCT Blood Tests Function in GP Surgeries
Participants provide one or two tubes of blood during a routine GP appointment alongside standard blood tests, as reported by The Coventry Observer.
The tests examine biomarkers, analysing protein patterns analysed using artificial intelligence to identify potential cancer signals and suggest where in the body they originate.
The evaluation covers a wide range of malignancies, including bowel, small bowel, stomach, oesophageal, pancreatic, liver, bile duct, gallbladder, ovarian, endometrial, kidney, bladder, and prostate cancers according to Aol.
Participating practices have been randomly allocated, with half offering eligible patients a blood test alongside usual care while the other half provide usual care alone as detailed by GPonline.
Doctors participating in the trial also record how strongly they suspect cancer so researchers can assess how effectively the tests function alongside clinical judgment noted Pharmacy Magazine.
Officials emphasize that the blood tests will not provide a definitive diagnosis. A positive result indicates that a patient requires an urgent referral for further investigation, while a negative result does not provide a guaranteed all-clear reported Pharmacy Business.
200 GP practices in England are to offer patients a new blood test which can detect 13 types of cancer – as part of a groundbreaking NHS trial. Patients with symptoms like abdominal discomfort or bloating will be invited to take part in the trial, led by Birmingham University.… pic.twitter.com/JM72X6pSaA
Detecting Abdomen Cancer Early Remains Notoriously Difficult
In England, approximately 71,000 people are diagnosed each year with pancreatic, stomach, liver, ovarian, or bowel cancer, resulting in nearly 35,000 deaths according to the BBC.
Roughly nine in ten patients diagnosed at stage 1 survive for at least five years. Survival drops to about one in ten for bowel cancer when diagnosed at stage 4, noted FemTech World.
Detecting abdomen cancer early is notoriously difficult because the symptoms can easily be mistaken for other less serious conditions, but the NHS is determined to find a solution.
Professor Peter Johnson, NHS England’s national clinical director for cancer
According to Health Minister James Frith, a period of 18 to 24 months may be required to ascertain whether any of the tests prove appropriate for a national rollout.
GPs have long needed better tools to help them navigate that uncertainty by identifying which patients require further testing and this trial in England is an important step towards addressing that need.
Michelle Mitchell, chief executive of Cancer Research UK
The initiative follows an earlier NHS evaluation involving more than 142,000 volunteers who tested a different multi-cancer detection product called Galleri reported by The Coventry Observer.
That study did not meet its primary objective of reducing late-stage cancer diagnoses across 12 specified types noted King’s College London.
We are at the start of revolution in cancer diagnosis, and this trial will help us to find out whether blood tests can help GPs get the right patients to the right tests sooner, supporting earlier diagnosis when treatment is most likely to be successful. https://t.co/phQjUMi9I1
Researchers are now examining whether testing symptomatic patients yields more actionable clinical outcomes.
Government Supplies Financial Backing Reaching up to Million
Financial backing for the programme reaches up to £8.49 million, supplied by the government via the Office for Life Sciences through the National Institute for Health and Care Research (NIHR).
Participating practices serve inner-city, rural, coastal, and deprived communities to ensure findings apply broadly across the healthcare system stated FemTech World.
Too many patients with cancer reach me after months of vague symptoms that were hard to pin down. At the same time, most people referred urgently do not have cancer, causing unnecessary worry and expense. These blood tests might help GPs tell the two apart, but we need to know for certain before they are used across the NHS, and this trial is designed to give that answer quickly.
Professor Aneel Bhangu, consultant colorectal surgeon and co-chief investigator of the trial
Health and Social Care Secretary Yvette Cooper noted that the trial will establish whether simple blood tests help primary care doctors identify patients needing urgent support much sooner.
Earlier coverage: NHS Trials Multi-Cancer Blood Tests in 200 GP Surgeries